Company intelligence / Profile preview

AIS Biotech

Grenoble, Auvergne-Rhône-Alpes, Franceaisnet.org ↗

Ownership: Private
Employees: ~4
Development stage: Other

Overview

AIS Biotech is developing a new class of sugar-based anti-infective agents that act as decoy receptors to prevent pathogens from binding to host cells. Their lead candidate targets influenza and is in preclinical development. The company leverages over two decades of academic research and aims to address both existing and emerging infectious threats, including those with antibiotic resistance concerns. No clinical results have been published yet; the company was founded in March 2023 and has received recognition as an innovative startup in France.

Therapeutic areas: Infectious Diseases
Modalities: GlycomimeticBiomaterialsSmall molecule
Industry: Biotech

Partnerships

Academic partnership with CERMAV, CNRS GrenobleSupported by SATT Linksium technology transfer officeMember of Lyonbiopole cluster

Beyond the preview

Go deeper on AIS Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIS Biotech.

Explore the full profile